<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008731</url>
  </required_header>
  <id_info>
    <org_study_id>2020-005742-42</org_study_id>
    <nct_id>NCT05008731</nct_id>
  </id_info>
  <brief_title>Effect of Botulinum Toxin on Hamstring Contracture and the Occurrence of Cyclops Syndrome After Anterior Cruciate Ligament Reconstruction</brief_title>
  <acronym>SCALA</acronym>
  <official_title>Effect of Botulinum Toxin on Hamstring Contracture and the Occurrence of Cyclops Syndrome After Anterior Cruciate Ligament Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric, prospective, randomised, double-blind study of two parallel groups of 66&#xD;
      patients with post-reconstruction ACL hamstring contracture treated with an ultrasound-guided&#xD;
      injection at two points on the body of the hamstring&#xD;
&#xD;
        -  Group 1: botulinum toxin: 100 units (0.5ml) in 1 injection&#xD;
&#xD;
        -  Group 2: placebo: 0.5 ml in 1 injection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes three assessments: one month after ligamentoplasty (inclusion visit) and&#xD;
      then at M2 and M5. The therapeutic benefit of the study treatments is based on the evolution&#xD;
      of the extension defect at M2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric, prospective, randomised, double-blind study of two parallel groups of 66 patients with post-reconstruction ACL hamstring contracture treated with an ultrasound-guided injection at two points on the body of the hamstring&#xD;
Group 1: botulinum toxin: 100 units (0.5ml) in 1 injection&#xD;
Group 2: placebo: 0.5 ml in 1 injection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>A placebo is used</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of therapeutic success, defined by the absence of extension defect at M3 post ligamentoplasty, will be compared between the groups by a Chi-2 test.</measure>
    <time_frame>Month 2</time_frame>
    <description>Therapeutic success is defined by the absence of extension defect (0 degree of flessum) at 2 months post botulinum toxin injection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Hamstring Contractures</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin: 100 units (0.5ml) in 1 injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 0.5 ml in 1 injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin</intervention_name>
    <description>100 units (0.5ml) in 1 injection</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 0.5 ml in 1 injection</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Patient who has read and signed the consent form for participation in the study&#xD;
&#xD;
          -  Patient operated on for primary ACL ligamentoplasty with or without meniscal repair&#xD;
&#xD;
          -  Patient with reducible flatus &gt;10° at 1 month post ligamentoplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revision ligamentoplasty&#xD;
&#xD;
          -  Multi-ligament knee&#xD;
&#xD;
          -  Patient under court protection, guardianship or trusteeship&#xD;
&#xD;
          -  Patient not affiliated to the French social security system&#xD;
&#xD;
          -  Patient participating in another therapeutic protocol&#xD;
&#xD;
          -  Pregnant woman or woman of childbearing age without effective contraception&#xD;
&#xD;
          -  Patient unable to understand the informed information and/or to give written informed&#xD;
             consent: dementia, psychosis, disturbed consciousness, non-French speaking patient&#xD;
&#xD;
          -  Patient with known hypersensitivity to botulinum toxin&#xD;
&#xD;
          -  Patient with peripheral neuromuscular dysfunction or pronounced atrophy of the&#xD;
             semitendinosus muscle&#xD;
&#xD;
          -  Patient treated with anticoagulants, chloroquine (or hydroxychloroquine)&#xD;
&#xD;
          -  Patient treated in the previous seven days with antibiotics or muscle relaxants (such&#xD;
             as tubocurarine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Hardy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique du sport</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Hardy, MD</last_name>
    <phone>189164500</phone>
    <phone_ext>33</phone_ext>
    <email>alexandre.hardy@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique du Sport</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

